Acuta Capital Partners, LLC Arvinas, Inc. Transaction History

Acuta Capital Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $2.83 Million - $4.47 Million	-123,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$29.88 - $56.74 $4.69 Million - $8.91 Million	-157,120 Reduced 56.09%	123,000 $4.13 Million
Q1 2020 May 15, 2020	SELL	$33.0 - $54.5 $2.5 Million - $4.14 Million	-75,880 Reduced 21.31%	280,120 $11.3 Million
Q4 2019 Feb 14, 2020	SELL	$15.39 - $44.38 $3.24 Million - $9.34 Million	-210,500 Reduced 37.16%	356,000 $14.6 Million
Q3 2019 Nov 14, 2019	BUY	$21.55 - $27.61 $334,025 - $427,955	15,500 Added 2.81%	566,500 $12.2 Million

Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $3.78 Million - $5.64 Million	237,000 Added 75.48%	551,000 $12.1 Million
Q1 2019 May 14, 2019	BUY	$13.55 - $23.79 $4.25 Million - $7.47 Million	314,000 New	314,000 $4.64 Million

234

64.9M

119K

94.2K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.42B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.